Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and ...

Acoramidis is the first therapy shown to potentially reverse cardiac structural disease progression and functional decline in transthyretin amyloid cardiomyopathy (ATTR-CM), significantly increasing days alive and out of hospital. Data from a Phase 3 study demonstrated improved left ventricular function in over half of treated patients and long-term safety through 54 months, supporting a shift toward restoring heart health in ATTR-CM patients.

This Wire brief sits within Fusion42's coverage of Biotech.